Grifols SA logo

Grifols SANASDAQ: GRFS

Profile

Sector:

Healthcare

Country:

Spain

IPO:

02 June 2011

Next earnings report:

28 February 2025

Last dividends:

03 June 2021

Next dividends:

N/A
$5.91 B
-34%vs. 3y high
90%vs. sector
-55%vs. 3y high
68%vs. sector
-32%vs. 3y high
38%vs. sector
-80%vs. 3y high
24%vs. sector

Price

regular market | 6 min ago
$8.69+$0.15(+1.76%)

Dividend

No data over the past 3 years
$1.97 B$1.85 B
$1.97 B$56.85 M

Analysts recommendations

Institutional Ownership

GRFS Latest News

Grifols' Board Rejects Brookfield's Buyout Offer, Stock Down 8%
zacks.com20 November 2024 Sentiment: NEGATIVE

Per GRFS, Brookfield's offer to buy its entire outstanding share capital for 6.45 billion euros significantly undervalues GRFS' prospects and long-term potential.

Mason Capital Reiterates Corporate Governance Shortcomings and Mismanagement of Grifols Under Current Board of Directors
businesswire.com19 November 2024 Sentiment: NEGATIVE

NEW YORK--(BUSINESS WIRE)--Mason Capital Management LLC (“Mason”), a registered investment advisor to funds and accounts holding approximately 2.1% of Grifols S.A. (“Grifols” or the “Company”) (BME: GRF) (NASDAQ: GRFS) class A shares, today sent a letter to the Grifols Board of Directors (the “Board”). In the letter, Mason reiterated the Company's corporate governance deficiencies, which have inflicted large losses on all shareholders and resulted in a rumored take-private by affiliates of Broo.

Grifols: Here Is Why It's Still A 'Buy' Even If Price Goes Down
seekingalpha.com03 October 2024 Sentiment: POSITIVE

Grifols, S.A. is undervalued and worth more than its current market valuation, making it a strong buy even without a potential Brookfield buyout. The company leads the global plasma market, with significant growth in immunoglobulin and albumin segments, and has a robust infrastructure and geographical reach. Despite facing competition and emerging technologies, Grifols' fundamentals are solid, with impressive 2024 earnings forecasts and improving margins and leverage.

Grifols plans to invest $402 million in new industrial centre, El Economista says
reuters.com30 September 2024 Sentiment: POSITIVE

Spanish drugmaker Grifols plans to invest 360 million euros ($401.98 million) to build a new industrial plant in Barcelona for its engineering department, newspaper El Economista said on Monday, citing unidentified company sources.

Grifols Egypt Collaborates with Orange Business to Deliver New Data Center and Communications Infrastructure, Supporting Advanced Medical Processes
businesswire.com11 September 2024 Sentiment: POSITIVE

CAIRO--(BUSINESS WIRE)--Orange Business is pleased to announce the successful completion of the first phase of a new data center and communications infrastructure for Grifols Egypt for its Plasma Derivatives (GEPD) facility in the Medical City within the New Administrative Capital. The partnership involves delivering co-location services through the ACUD (Administrative Capital for Urban Development) commercial and telco data center. This includes communication services, support in equipment pr.

The Schall Law Firm Wants The Public To Participate In An Investigation Into Grifols S.A.'s Possible Securities Law Violations
accesswire.com31 August 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / August 31, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grifols, S.A. ("Grifols" or "the Company") (NASDAQ:GRFS) for violations of the securities laws.

Grifols SA May Have Committed Securities Fraud And Stakeholders Are Invited To Join The Schall Law Firm's Inquiry
accesswire.com30 August 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / August 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grifols, S.A. ("Grifols" or "the Company") (NASDAQ:GRFS) for violations of the securities laws.

The Schall Law Firm Is Looking Into Whether Grifols S.A. Violated Securities Regulations And Investors Are Urged To Reach Out
accesswire.com29 August 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / August 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grifols, S.A. ("Grifols" or "the Company") (NASDAQ:GRFS) for violations of the securities laws.

Why Grifols (GRFS) Stock Price Moved Up 7% on Wednesday
zacks.com22 August 2024 Sentiment: POSITIVE

A Bloomberg article suggests that Brookfield Asset Management is in discussions with banks to raise nearly $11 billion to fund the takeover of Spain-based Grifols (GRFS).

Grifols SA Is Being Looked Into By The Schall Law Firm And We Urge Impacted Investors To Join
accesswire.com15 August 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / August 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grifols, S.A. ("Grifols" or "the Company") (NASDAQ:GRFS) for violations of the securities laws.

What type of business is Grifols SA?

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain.

What sector is Grifols SA in?

Grifols SA is in the Healthcare sector

What industry is Grifols SA in?

Grifols SA is in the Drug Manufacturers - General industry

What country is Grifols SA from?

Grifols SA is headquartered in Spain

When did Grifols SA go public?

Grifols SA initial public offering (IPO) was on 02 June 2011

What is Grifols SA website?

https://www.grifols.com

Is Grifols SA in the S&P 500?

No, Grifols SA is not included in the S&P 500 index

Is Grifols SA in the NASDAQ 100?

No, Grifols SA is not included in the NASDAQ 100 index

Is Grifols SA in the Dow Jones?

No, Grifols SA is not included in the Dow Jones index

When was Grifols SA the previous earnings report?

No data

When does Grifols SA earnings report?

The next expected earnings date for Grifols SA is 28 February 2025